Kedrion Biopharma has always been committed to broadening access to plasmaderivate therapies worldwide for the treatment of hemophilia. We do so also by supporting ethical, transparent and sustainable projects aimed at disadvantaged Countries. Kedrion restates its dedication during World Hemophilia Day celebrated worldwide on 17 April 2016.
In Italy, Kedrion has been at the side of FedEmo (Federation of Hemophilia Associations) by taking part in the meeting entitled "Innovative therapies for hemophilia; developing care and sustainability", held in Rome on the 11th of April. The roundtable was moderated by Radio 24 journalist Nicoletta Carbone with the participation of associations of patients, clinicians, companies, representatives of the Ministries and of AIFA. After an initial press conference on innovative therapies, the event hosted two panel discussions on the access criteria to hemophilia clinical trials and on the new treatments for hepatitis.
Kedrion Biopharma will also support the Fondazione Paracelso in Milan at the annual conference entitled "Disease. Let’s transform it into energy” on 21 April. An excellent opportunity for patient groups, clinicians, companies, political institutions, administrative representatives and members of the press to discuss hemophilia from a different point of view; framing the disease not only as an event that concerns the physical body of the person who is affected, but also has an impact the social body in which that person lives.
In the US, Kedrion Biopharma will make a donation to the international nonprofit organization Save One Life, which helps patients with bleeding disorders and their families in developing countries.
Kedrion’s commitment to hemophilia patient communities around the world goes well beyond the events linked to World Hemophilia Day. In 2015, the company promoted the creation of WISH, a humanitarian program underwritten by the World Federation of Hemophilia (WFH) and the Italian National Blood Centre (CNS), geared at reducing differences in access to clotting factor concentrates around the world. Moreover, with the same goal, Kedrion has given its full support to the WFH’s Global Alliance for Progress program (GAP), also backing a multidisciplinary hemophilia symposium in Namibia.
For 2016, Kedrion has renewed its support to the World Congress of the World Federation of Hemophilia; an event that is specifically targeted at patients and which this year will take place in July, in Orlando, Florida (USA).